Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

Published:2013-04-11 Issue:1 Volume:11 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Suzuki Hiroyuki,Fukuhara Mitsuro,Yamaura Takumi,Mutoh Satoshi,Okabe Naoyuki,Yaginuma Hiroshi,Hasegawa Takeo,Yonechi Atsushi,Osugi Jun,Hoshino Mika,Kimura Takashi,Higuchi Mitsunori,Shio Yutaka,Ise Kazuya,Takeda Kazuyoshi,Gotoh Mitsukazu

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1479-5876-11-97.pdf

Reference34 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.

2. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC: Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012, 307: 2418-2429.

3. Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS: Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol. 2011, 68: 1099-1109. 10.1007/s00280-011-1737-2.

4. Ricciardi S, Tomao S, de Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009, 10: 28-35. 10.3816/CLC.2009.n.004.

5. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard VG: Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2007, 25: s7554-

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of cell division cycle-associated proteins in regulating cell cycle and promoting tumor progression;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction;Chinese Medical Journal;2024-08-28

3. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma;Esophagus;2024-07-11

4. Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer;Molecular Therapy: Oncology;2024-03

5. Cancer vaccines: from an immunology perspective;Immunotherapy Advances;2023-12-21